Official ESCRS | European Society of Cataract & Refractive Surgeons
Athens 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings
ATHENS escrs


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Nepafenac 0.1% an ophthalmic non steroidal anti-inflammatory drug for the prevention of cystoid macular edema after phacoemulsification

Poster Details

First Author: E.Stangogianni GREECE

Co Author(s):    C. Stangogianni              

Abstract Details


To determine the efficacy of nepafenac ophthalmic suspension 0.1% as unique non steroidal anti-inflammatory therapy in prevention of cystic macular edema following cataract surgery.


Laselens. Ophthalmology Institute. Ioannina-Greece


Prospective, descriptive and interventional study. Which include 60 patient’s, both gender that required torsional phacoemulsification, intraocular lens and with uncomplicated cataract surgery. Nepafenac drop was administered in ophthalmic suspension 0.1% three times a day beginning one day prior to surgery through day 30 post-op. In the ophthalmological exam (1, 7 and 45 days) was evaluated the visual acuity and visual capacity, intraocular pressure, the cellular and flare in the anterior chamber. Optical coherent tomography, macular and retinal fluoroangiography was carried out to every patient as well in order to dismiss the presence of cystoid macular edema or subclinical edema.


An adequate non steroidal anti-inflammatory response was observed using the nepafenac as unique therapy in patients with uncomplicated cataract surgery. We found an important reduction in the incidence of CME and of the subclinical edema with its topical administration.


The use of nepafenac preoperative to phacoemulsification and implant of IOL is effective to control the postoperative inflammation with limited adverse symptoms. FINANCIAL DISCLOUSRE: NONE

Back to Poster listing